Asset
ZANZALINTINIB
Revenue
No revenue reported in loaded filings.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06952010 | phase1 | recruiting | 2025-05-01 | 2027-05-31 | Exelixis | A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors |
| NCT03845166 | phase1 | active_not_recruiting | 2019-03-20 | 2026-08-31 | Exelixis | A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors |
| NCT07428616 | phase2 | recruiting | 2026-05-21 | 2028-02-29 | Exelixis | A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma |
| NCT07620574 | phase3 | enrolling_by_invitation | 2026-07-30 | 2030-05-31 | Exelixis | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study |
| NCT06962332 | phase1 | recruiting | 2025-05-13 | 2025-12-01 | Exelixis | Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI) |
FDA applications (0)
This company has no applications containing this asset.